Core Viewpoint - The stock price of Peijia Medical-B (02565.HK) fell by 5.54% to HKD 63.05 on February 13, primarily due to a combination of market weakness, profit-taking after index inclusion, technical pressure, funding discrepancies, and high valuation concerns [1][5]. Stock Performance - On February 13, the Hang Seng Index dropped by 1.72%, and the biotechnology sector declined by 0.95%, indicating increased risk aversion in the market, leading to capital outflows from growth sectors like pharmaceuticals [2]. Reasons for Stock Price Movement - Peijia Medical-B was announced to be included in the Hang Seng Composite Index effective March 9, 2026. However, this positive news was partially anticipated by the market, as the stock had already risen approximately 4.7% over February 11 and 12. On February 13, the stock opened high but fell after reaching a peak of HKD 67.40, suggesting profit-taking by some investors [3]. Funding and Technical Analysis - The closing price of HKD 63.05 on February 13 was below both the 5-day moving average (HKD 65.27) and the 20-day moving average (HKD 65.515). The MACD histogram, while positive, remained below the zero line, indicating a bearish short-term trend. The stock experienced a volatility of 9.51%, with a low of HKD 61.05, near the lower Bollinger Band (HKD 58.974), reflecting strong selling pressure. Although there was a net inflow of HKD 335.67 million, it was primarily driven by retail investors, with institutional investors showing a cautious stance [4]. Company Valuation - As of February 13, the company's trailing twelve months (TTM) price-to-earnings ratio was -101.56, and the price-to-book ratio was 42.84, indicating a high valuation level. The company’s R&D expenditure for the mid-2025 period was HKD 26.294 million, suggesting significant ongoing investment pressure. Market concerns may arise regarding the alignment of its earnings outlook with current valuation levels [5].

Core Viewpoint - Xirui (02507) shares rose over 8%, reaching a new high of 69.45 HKD since August last year, with a trading volume of 54.2 million HKD [1] Group 1: Company Performance - Haitong International forecasts that Xirui will deliver approximately 800 aircraft in 2025, with around 600 new orders expected [1] - The company is expected to meet the requirements for market capitalization, trading volume, and turnover rate set by index companies by the end of 2025 [1] Group 2: Product Development - On February 3, Xirui launched the VisionJet G3, which features price increases and upgrades in intelligence and comfort [1] - West Securities believes that with the introduction of better-structured products like VisionJet G3 and SRG7+, the overall product structure will improve year-on-year, leading to enhanced profitability [1]

Core Viewpoint - Xirui (02507) shares rose over 8%, reaching a new high of 69.45 HKD since August last year, with a trading volume of 54.20 million HKD [1] Group 1: Company Performance - Haitong International forecasts that Xirui will deliver approximately 800 aircraft in 2025, with around 600 new orders expected [1] - The company is expected to meet the requirements for market capitalization, trading volume, and turnover rate set by index companies by the end of 2025 [1] Group 2: Product Development - On February 3, Xirui launched the VisionJet G3, which features price increases and upgrades in intelligence and comfort [1] - West Securities believes that with the introduction of better-structured products like VisionJet G3 and SRG7+, the overall product structure will improve year-on-year, enhancing profitability [1]

Core Viewpoint - Minglue Technology (2718.HK) debuted on the Hong Kong Stock Exchange with a closing increase of 106.1%, reaching a market capitalization of HKD 41.956 billion, indicating strong market demand with an oversubscription of 4452.86 times in the public offering and 13.93 times in the international offering [1] Group 1: Lock-up Periods for Shareholders - The cornerstone investors of Minglue Technology have a lock-up period of 270 days, which is 50% longer than the standard 180 days for cornerstone investors in Hong Kong, aimed at stabilizing stock prices before inclusion in the Stock Connect program [2] - The controlling shareholder has a lock-up period of 12 months, consistent with the standard rules for the main board in Hong Kong, which prohibits any share sales for the first 6 months and restricts sales in the following 6 months to maintain control [3][5] - Non-controlling shareholders have a lock-up period of 270 days, which is approximately 26% shorter than the customary 365 days, to balance liquidity and stability given the small float of the company [6][7] Group 2: Special Arrangements - The extended lock-up for cornerstone investors is designed to prevent share sales that could negatively impact stock prices during a critical period before the company qualifies for Stock Connect [2] - The controlling shareholder's additional commitment to a 12-month lock-up for B shares is an extra constraint rather than a regulatory requirement, maintaining alignment with standard practices [5] - The overall lock-up arrangements reflect a targeted adjustment strategy, extending the lock-up for cornerstone investors while aligning other shareholders with standard practices or shortening their periods to ensure liquidity [8]

Core Viewpoint - The report from GF Securities highlights the significant stock price increase of Horizon Robotics (09660) by 11.4% after being included in the Hong Kong Stock Connect, suggesting a potential timing opportunity based on capital flow [1] Group 1: Market Behavior Post Inclusion - After being included in the Stock Connect, leading companies often experience immediate capital inflow, resulting in stock price increases, with the steepest inflow observed in the initial days [2] - However, the short-term price increase is not universally applicable to all companies, indicating that this is not a straightforward quantitative timing strategy [2] - This strategy is more effective for high-quality leading companies that have been thoroughly researched and recognized by active funds, which are likely to buy quickly after inclusion [2] Group 2: Future Inclusion Candidates - There are two fixed "inclusion" periods each year: the first week of March and September, with the next inclusion effective the following Monday, primarily based on the company's inclusion in the Hang Seng Composite Index [3] - Additionally, there are quarterly rapid inclusions for newly listed companies, which are subject to specific criteria such as average market capitalization [3][4] - Potential companies for future inclusion include: - June 6: Bruker, Mixue Group, and Gu Ming [5][6] - Late June: CATL and Hengrui Medicine [5][6] - September 5: Companies like Conant Optical and others [5][6]